963 related articles for article (PubMed ID: 24346250)
21. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of menopausal therapies on the endometrium.
Mirkin S; Archer DF; Taylor HS; Pickar JH; Komm BS
Menopause; 2014 Aug; 21(8):899-908. PubMed ID: 24518153
[TBL] [Abstract][Full Text] [Related]
23. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
Gallagher JC; Shi H; Mirkin S; Chines AA
Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
[TBL] [Abstract][Full Text] [Related]
24. Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).
Lindsay R
Osteoporos Int; 2011 Feb; 22(2):447-51. PubMed ID: 21069294
[TBL] [Abstract][Full Text] [Related]
25. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
26. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
Pinkerton JV; Stovall DW
Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
[TBL] [Abstract][Full Text] [Related]
27. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
28. What do TSECs provide in the menopausal hormone therapy?
Llaneza P; Calaf J; Jurado AR; Mendoza N; Otero B; Quereda F; Sánchez-Borrego R; Lubian D
Gynecol Endocrinol; 2018 Oct; 34(10):826-832. PubMed ID: 29790381
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Lindsay R; Gallagher JC; Kagan R; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS
Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
32. Tissue selective estrogen complex (TSEC): a review.
Pickar JH; Boucher M; Morgenstern D
Menopause; 2018 Sep; 25(9):1033-1045. PubMed ID: 29533367
[TBL] [Abstract][Full Text] [Related]
33. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
34. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV
Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
[TBL] [Abstract][Full Text] [Related]
35. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS
Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562
[TBL] [Abstract][Full Text] [Related]
36. Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy.
Komm BS; Mirkin S
Int J Womens Health; 2012; 4():129-40. PubMed ID: 22505832
[TBL] [Abstract][Full Text] [Related]
37. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.
Pickar JH; Yeh IT; Bachmann G; Speroff L
Fertil Steril; 2009 Sep; 92(3):1018-1024. PubMed ID: 19635613
[TBL] [Abstract][Full Text] [Related]
38. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
[TBL] [Abstract][Full Text] [Related]
39. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
[TBL] [Abstract][Full Text] [Related]
40. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]